Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nelfinavir mesylate.

P Tebas1, W G Powderly

  • 1Division of Infectious Diseases, Washington University School of Medicine, Box 8051, St. Louis, MO 63110, USA. tebas@im.wustl.edu

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.

HIV medicine·2017
Same author

High IP-10 levels decrease T cell function in HIV-1-infected individuals on ART.

Journal of leukocyte biology·2014
Same author

Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2013
Same author

Rifabutin induced vitritis in AIDS patients.

Ocular immunology and inflammation·2012
Same author

Progenitor cell types in HIV-1 infection: bioactivity and emerging targets for treatment.

Current HIV research·2009
Same author

Sub-optimal CD4 recovery on long-term suppressive highly active antiretroviral therapy is associated with favourable outcome.

HIV medicine·2009
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Nelfinavir, an HIV protease inhibitor, effectively reduces viral load and increases CD4+ counts when used with other antiretrovirals. It is well-tolerated and remains a preferred first-line protease inhibitor for HIV treatment.

Area of Science:

  • Pharmacology
  • Virology
  • Immunology

Background:

  • Nelfinavir is a potent inhibitor of HIV-1 and HIV-2 protease.
  • It is utilized in combination therapy for managing HIV-infected patients.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of nelfinavir in combination antiretroviral therapy.
  • To assess the impact of nelfinavir on viral load and CD4+ lymphocyte counts.

Main Methods:

  • Clinical trials and patient data analysis.
  • Assessment of plasma HIV RNA levels and CD4+ lymphocyte counts.
  • Monitoring for side effects and virologic failure patterns.

Main Results:

  • 50-75% of treatment-naïve patients achieved undetectable HIV RNA levels (<400 copies/mL) after 12 months.

Related Experiment Videos

  • An increase of nearly 200/mm³ in CD4+ lymphocytes was observed.
  • Nelfinavir demonstrated equipotency to other protease inhibitors with mild diarrhea as the most common side effect (12-20%).

    • Conclusions:

    • Nelfinavir is an effective and well-tolerated first-line protease inhibitor for HIV treatment.
    • Its unique resistance profile may allow for salvage therapy with subsequent protease inhibitor regimens.
    • Nelfinavir is a frequently prescribed first-line protease inhibitor due to its favorable characteristics.